ISPOR - PDG61 TYPES OF ENDPOINTS OF NEW MOLECULAR ENTITIES APPROVED BY THE FDA: THE INCREASING IMPORTANCE OF PATIENT-REPORTED OUTCOMES

PDG61 TYPES OF ENDPOINTS OF NEW MOLECULAR ENTITIES APPROVED BY THE FDA: THE INCREASING IMPORTANCE OF PATIENT-REPORTED OUTCOMES

Abstract

Authors

R. Tan T. McLaughlin A. Duhig

Full Text Cite This Article

Back to Volume 23, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now